Back to search

Peptide record

TPDB92109

Cecropin A Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92109
Cecropin A
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept dbAMP 3.0 AI4AVP DRAVP 2.0
standard
No
A 37-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2
Physicochemical Analysis
C184H312N52O47
CHMSY
K
4004.82
10.91
8
2
17
+6
8.12
-0.073
108.11
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
137.33
5
Residue Composition
number
5
A
1
R
1
N
1
D
0
C
1
E
3
Q
4
G
0
H
5
I
1
L
7
K
0
M
1
F
1
P
0
S
1
T
1
W
0
Y
4
V
Amino Acid Distribution
A: 5 R: 1 N: 1 D: 1 C: 0 E: 1 Q: 3 G: 4 H: 0 I: 5 L: 1 K: 7 M: 0 F: 1 P: 1 S: 0 T: 1 W: 1 Y: 0 V: 4
Chemical Descriptors
37
C184H312N52O47
4004.82
10.91
+6
8.12
-0.073
Amidation
L
Linear
Free
Antimicrobial
Hyalophora Cecropia(silkmoth)
Evidence Records 12 records
Evidence 1 Activity

Activity

IC50
IC50=251.47 µg/ml
Anticancer
251.47 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

IC50
IC50=231.26 µg/ml
Anticancer
231.26 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 3 Activity

Activity

IC50
IC50=185.39 µg/ml
Anticancer
185.39 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 4 Activity

Activity

IC50
IC50=212.07 µg/ml
Anticancer
212.07 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 5 Activity

Activity

IC50
IC50=69.2 µg/ml
Anticancer
69.2 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 6 Activity

Activity

IC50
IC50=96.22 µg/ml
Anticancer
96.22 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 7 Activity

Activity

IC50
IC50=28.74 µg/ml
Anticancer
28.74 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 8 Activity

Activity

IC50
IC50=99.01 µg/ml
Anticancer
99.01 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 9 Activity

Activity

IC50
IC50=373.3/ µg/ml
Anticancer
373.3

Target

Bladder Cancer
486P
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 10 Activity

Activity

IC50
IC50=289.3 µg/ml
Anticancer
289.3 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 11 Activity

Activity

IC50
IC50=200.7 µg/ml
Anticancer
200.7 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 12 Activity

Activity

IC50
IC50=319.2 µg/ml
Anticancer
319.2 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008